Volume 1045 2013

Antibody-Drug Conjugates

Editors:

ISBN: 978-1-62703-540-8 (Print) 978-1-62703-541-5 (Online)

Table of contents (20 protocols)

  1. Front Matter

    Pages i-x

  2. No Access

    Book Protocol

    Pages 1-27

    Antibody–Drug Conjugate (ADC) Clinical Pipeline: A Review

  3. No Access

    Book Protocol

    Pages 29-40

    Antibody–Drug Conjugate Target Selection: Critical Factors

  4. No Access

    Book Protocol

    Pages 41-49

    Selecting an Optimal Antibody for Antibody–Drug Conjugate Therapy: Internalization and Intracellular Localization

  5. No Access

    Book Protocol

    Pages 51-70

    Antibody–Drug Conjugate Payloads

  6. No Access

    Book Protocol

    Pages 71-100

    Linker Technologies for Antibody–Drug Conjugates

  7. No Access

    Book Protocol

    Pages 101-116

    In Vivo Testing of Drug-Linker Stability

  8. No Access

    Book Protocol

    Pages 117-131

    Pharmacokinetics and ADME Characterizations of Antibody–Drug Conjugates

  9. No Access

    Book Protocol

    Pages 133-143

    Safe Handling of Cytotoxic Compounds in a Biopharmaceutical Environment

  10. No Access

    Book Protocol

    Pages 145-171

    Micro- and Mid-Scale Maleimide-Based Conjugation of Cytotoxic Drugs to Antibody Hinge Region Thiols for Tumor Targeting

  11. No Access

    Book Protocol

    Pages 173-187

    Protocols for Lysine Conjugation

  12. No Access

    Book Protocol

    Pages 189-203

    Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers

  13. No Access

    Book Protocol

    Pages 205-215

    Enzymatic Antibody Modification by Bacterial Transglutaminase

  14. No Access

    Book Protocol

    Pages 217-233

    Formulation Development of Antibody–Drug Conjugates

  15. No Access

    Book Protocol

    Pages 235-248

    Conjugation Process Development and Scale-Up

  16. No Access

    Book Protocol

    Pages 249-266

    Methods for Conjugating Antibodies to Nanocarriers

  17. No Access

    Book Protocol

    Pages 267-273

    Drug-to-Antibody Ratio (DAR) by UV/Vis Spectroscopy

  18. No Access

    Book Protocol

    Pages 275-283

    Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by Hydrophobic Interaction Chromatography and Reversed Phase High-Performance Liquid Chromatography

  19. No Access

    Book Protocol

    Pages 285-293

    Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS

  20. No Access

    Book Protocol

    Pages 295-302

    Determination of Charge Heterogeneity and Level of Unconjugated Antibody by Imaged cIEF

  21. No Access

    Book Protocol

    Pages 303-311

    Risk-Based Scientific Approach for Determination of Extractables/Leachables from Biomanufacturing of Antibody–Drug Conjugates (ADCs)

  22. Back Matter

    Pages 313-317